急性心力衰竭治疗的新药重组人松弛素  

Serelaxin:a Potential New Drug for the Treatment of Acute Heart failure

作　　者：张永珍[1] 周元祎 

机构地区：[1]北京大学第三医院心内科卫生部心血管分子生物学与调节肽重点实验室及分子心血管学教育部重点实验室,北京100191

出　　处：《临床药物治疗杂志》2014年第5期16-20,共5页Clinical Medication Journal

基　　金：国家"十二五"科技支撑计划(2011BAI11B08);北京市自然科学基金(7122200)

摘　　要：目的:最近重组人松弛素的临床试验为急性心力衰竭(AHF)的治疗提供了新的希望,笔者主要对重组人松弛素的作用机制、药理学特性、临床特征及治疗AHF的作用做一综述。方法:使用Pubmed/Medline database对文献进行查找,收集到21篇相关文献。结果 :研究表明重组人松弛素显著改善AHF患者的症状,缩短住院时间,降低病死率。目前的资料表明这些临床益处与重组人松弛素的多效性有关,包括改善全身、心脏和肾脏血流动力学,通过抗炎、抗细胞死亡、抗纤维化、抗心肌肥厚及促进血管新生保护细胞和器官免受损伤。结论 :重组人松弛素是一种有前景的治疗AHF药物。正在进行中的研究旨在验证先前的试验结果、安全性和血流动力学效应,探讨这些效应的分子机制。Objective：Recent clinical trials of serelaxin have provided a new hope in acute heart failure （AHF）.Serelaxin mechanisms,pharmacology,clinical features and its potential role in AHF are reviewed here.Methods：Twenty one articles were identified through a literature search of the Pubmed and Medline database.Results：Clinical trials have demonstrated significant serelaxin-related improvement in heart failure symptoms,length of hospital stay as well as mortality reduction in AHF patients.Available data suggested that the clinical benefits may be attributable to a potential combination of multiple actions of serelaxin,including improving systemic,cardiac,and renal hemodynamics,and protecting cells and organs from damage via anti-inflammatory,anti-cell death,anti-fibrotic,antihypertrophic,and pro-angiogenic effects.Conclusion：Serelaxin is a promising therapy,and further studies aimed at reproducibility of prior results,safety and hemodynamic effects of serelaxin,as well as investigation of the molecular reasons for such effects are currently under way.

关 键 词：急性心力衰竭 呼吸困难 重组人松弛素 血管扩张剂 

分 类 号：R541.6[医药卫生—心血管疾病]